Drug Information

Drug (ID: DG01820) and It's Reported Resistant Information

• Name: Cardamonin
• Synonyms: Cardamonin; 19309-14-9; 18956-16-6; CARDAMOMIN; Alpinetin chalcone; Dihydroxymethoxychalcone; 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; 2',4'-dihydroxy-6'-methoxychalcone; (E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; UNII-H8KP1OJ8JX; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-, (2E)-; H8KP1OJ8JX; CHEMBL378104; (E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; (E)-Cardamonin; (2E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; (E)-1-(2,4-Dihydroxy-6-methoxy-phenyl)-3-phenyl-propenone; (E)-1-(2,4-dihydroxy-6-methoxy-phenyl)-3-phenyl-prop-2-en-1-one; Cardamoni; (E)-Cardamoni; Cardamonin ,(S); 2'4'-Dihydroxy-6'-methoxy-chalcone; MLS000876992; SCHEMBL449220; MEGxp0_000534; Cardamonin, >=98% (HPLC); ACon1_000221; CHEBI:125601; CHEBI:186253; HMS2271N04; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-; HY-N0279; ZINC4716487; BDBM50185446; LMPK12120245; MFCD00238554; s3867; AKOS015896716; CCG-208127; DB14122; MCULE-6098713539; NCGC00180767-01; AC-34864; DS-15713; SMR000440601; B7085; CS-0008777; W1234; 309C149; A813330; J-012229; Q-100234; Q5038242; BRD-K61559475-001-01-0; 1-(2\\',4\\'-Dihydroxy-6\\'-methoxy-phenyl)-3-phenyl-propenone; (2E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; NCGC00180767-02!(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Gastric cancer [ICD-11: 2B72]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 4
• IsoSMILES: COC1=CC(=CC(=C1C(=O)/C=C/C2=CC=CC=C2)O)O
• InChI: InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+
• InChIKey: NYSZJNUIVUBQMM-BQYQJAHWSA-N
• PubChem CID: 641785
• DrugBank ID: DB14122

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Gastric cancer [ICD-11: 2B72]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Pvt1 oncogene (PVT1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Gastric adenocarcinoma [ICD-11: 2B72.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: BGC-823 cells; Gastric; Homo sapiens (Human); CVCL_3360
• In Vitro Model: MGC-803 cells; Gastric; Homo sapiens (Human); CVCL_5334
• In Vitro Model: AGS cells; Gastric; Homo sapiens (Human); CVCL_0139
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axis.

References

• Ref 1: Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axisBiosci Rep. 2019 May 17;39(5):BSR20190357. doi: 10.1042/BSR20190357. Print 2019 May 31.